Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NATAZIA vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Estetrol is a selective estrogen receptor modulator (SERM) with mixed agonist/antagonist activity; drospirenone is a spironolactone analog with antimineralocorticoid and antiandrogenic activity. Combined oral contraceptive inhibits ovulation and alters cervical mucus.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Prevention of pregnancy
Prevention of pregnancy
Drospirenone 3 mg / ethinyl estradiol 0.03 mg orally once daily for 21 days followed by 7 days of placebo.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Terminal half-life approximately 30 hours for drospirenone and 24 hours for ethinyl estradiol; steady-state achieved within 8–10 days.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Estetrol is metabolized primarily via glucuronidation (UGT1A1, UGT1A3, UGT1A9) and sulfation (SULT1E1). Drospirenone is metabolized via CYP3A4 and to a lesser extent by CYP1A1 and CYP2C9.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Fecal excretion is the primary route (approximately 68%), with renal excretion accounting for about 27% (mostly as metabolites).
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
Drospirenone: 95–97% bound to albumin (not to SHBG or CBG). Ethinyl estradiol: 98% bound to albumin.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Drospirenone: Vd approximately 0.7-1.0 L/kg. Ethinyl estradiol: Vd approximately 1.2-1.5 L/kg.
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Drospirenone: absolute oral bioavailability approximately 76–85%. Ethinyl estradiol: oral bioavailability approximately 40–50% (first-pass metabolism).
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
Contraindicated in patients with renal impairment (Cr Cl < 30 m L/min) due to risk of hyperkalemia. No dose adjustment required for mild to moderate impairment, but monitor serum potassium.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Contraindicated in acute liver disease or decompensated cirrhosis (Child-Pugh C). No dose adjustment for mild impairment (Child-Pugh A); use with caution in moderate impairment (Child-Pugh B) and monitor liver function.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Same as adult dosing for postmenarchal adolescents, but not indicated before menarche. Weight-based adjustments not established.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Not indicated for use in postmenopausal women; no specific dosing studies. In elderly with normal renal and hepatic function, standard dosing may be used, but consider increased risk of thromboembolism and cardiovascular events.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Thrombotic disorders (venous and arterial),Cerebrovascular disease,Myocardial infarction,Breast cancer risk,Liver disease,Hypertension,Hyperkalemia (drospirenone component),Carbohydrate and lipid metabolism effects,Headache/migraine,Uterine bleeding irregularities,Depression
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Current or history of venous or arterial thrombosis,Cerebrovascular disease,Myocardial infarction or coronary artery disease,Breast cancer or other estrogen- or progestin-sensitive cancer,Liver tumors (benign or malignant) or active liver disease,Undiagnosed abnormal uterine bleeding,Known or suspected pregnancy,Renal impairment (creatinine clearance <30 m L/min),Adrenal insufficiency,Hypersensitivity to any component,Smoking and age ≥35 years
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
Grapefruit and grapefruit juice may increase estrogen exposure and should be avoided. No other specific food interactions reported. Maintain a consistent diet to avoid variable contraceptive efficacy.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
Pregnancy Category X. First trimester: high risk of severe fetal malformations including CNS, cardiovascular, and craniofacial defects (e.g., neural tube defects, cardiac septal defects). Second and third trimesters: increased risk of fetal growth restriction, oligohydramnios, and neonatal renal impairment due to direct fetal toxicity.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Contraindicated during breastfeeding. No human data on M/P ratio; animal studies indicate significant excretion into milk with potential for severe adverse effects including growth retardation and renal toxicity in nursing infants.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
Not applicable; contraindicated in pregnancy. If inadvertent exposure occurs, discontinue immediately; no dose adjustment is recommended as the drug should be avoided entirely.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
NATAZIA (estradiol valerate/dienogest) is a four-phasic oral contraceptive. It is contraindicated in women with hepatic impairment, active liver disease, or a history of liver tumors. Due to the progestin dienogest, it may have antiandrogenic effects, beneficial for acne or hirsutism. Missed pills require specific instructions due to the dynamic dosing schedule; use a backup method if pills are missed during the first week.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take the pills in the exact order on the blister pack, starting with the first pill on the first day of your menstrual period.,Swallow the tablet whole with some liquid, with or without food.,If you vomit or have severe diarrhea within 3-4 hours of taking a pill, it may not be fully absorbed; consider it as a missed pill.,You may not have a withdrawal bleed every month; if you miss two withdrawal bleeds in a row, check for pregnancy.,NATAZIA does not protect against HIV or other sexually transmitted infections.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NATAZIA vs ALYACEN 7/7/7, answered by our medical review team.
NATAZIA is a Oral Contraceptive that works by Estetrol is a selective estrogen receptor modulator (SERM) with mixed agonist/antagonist activity; drospirenone is a spironolactone analog with antimineralocorticoid and antiandrogenic activity. Combined oral contraceptive inhibits ovulation and alters cervical mucus.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NATAZIA and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NATAZIA is: Drospirenone 3 mg / ethinyl estradiol 0.03 mg orally once daily for 21 days followed by 7 days of placebo.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NATAZIA and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NATAZIA is classified as Category C. Pregnancy Category X. First trimester: high risk of severe fetal malformations including CNS, cardiovascular, and craniofacial defects (e.g., neural tube defects, cardiac septal de. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.